Recalcitrant prurigo nodularis after COVID‐19 vaccination and successfully treated by dupilumab

Abstract

Abstract Prurigo nodularis (PN) is a chronic, inflammatory skin condition characterized by the presence of pruritic nodules. We report a 57‐year‐old woman in whom PN might have been induced by COVID‐19 vaccination. PN lesions started 2 days after she received the second dose of COVID‐19 vaccine. She had a poor response to a variety of treatments but achieved satisfactory efficacy after Dupilumab therapy, an interleukin‐4 receptor inhibitor.

Keywords

• biologicals
• COVID‐19
• Dupilumab
• Prurigo nodularis
• vaccine